EVH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Evolent Health Inc (EVH) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. While the stock has shown some positive price movement recently and analysts maintain a Buy rating, the company's financial performance, reduced price targets, and lack of significant positive catalysts suggest caution. The technical indicators and options data do not strongly support an immediate buy decision.
The MACD is positive and expanding, indicating bullish momentum. RSI is in the neutral zone at 78.251, suggesting no overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key resistance levels are at 2.921 and 3.145, while support levels are at 2.195 and 1.971.
Analysts maintain a Buy rating on the stock despite lowering price targets. The company's new CFO is implementing more conservative and transparent financial guidance, which could build investor confidence over time.
The company's Q4 2025 revenue dropped significantly (-27.50% YoY), and net income remains negative despite improvement. Analysts have significantly reduced price targets, citing concerns over debt leverage and visibility into EBITDA recovery. No recent news or significant insider/hedge fund activity to drive positive sentiment.
In Q4 2025, revenue dropped by -27.50% YoY to $468.7M. Net income improved but remains negative at -$429.1M. EPS increased to -3.85, up 1325.93% YoY, and gross margin improved to 11.14, up 55.15% YoY. However, the financials indicate ongoing challenges.
Analysts maintain a Buy rating but have significantly lowered price targets. UBS lowered the target to $5, Citi to $4, BTIG to $8, Truist to $6, and Canaccord to $4. KeyBanc downgraded the stock to Sector Weight, citing concerns over debt leverage and EBITDA recovery.
